Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
The purpose of this study was to evaluate antigen experienced T cells in peripheral blood lymphocytes (PBL) for responses to p53 neoantigens. PBLs from patients with a mutated tumor were sorted for antigen-experienced T cells and stimulation (IVS) was performed with p53 neoantigens. The IVS cultures...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2020-03, Vol.26 (6), p.1267-1276 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The purpose of this study was to evaluate antigen experienced T cells in peripheral blood lymphocytes (PBL) for responses to p53 neoantigens.
PBLs from patients with a mutated
tumor were sorted for antigen-experienced T cells and
stimulation (IVS) was performed with p53 neoantigens. The IVS cultures were stimulated with antigen-presenting cells expressing p53 neoantigens, enriched for 41BB/OX40 and grown with rapid expansion protocol.
T-cell responses were not observed in the PBLs of 4 patients who did not have tumor-infiltrating lymphocyte (TIL) responses to mutated
. In contrast, 5 patients with TIL responses to mutated
also had similar T-cell responses in their PBLs, indicating that the PBLs and TILs were congruent in p53 neoantigen reactivity. CD4
and CD8
T cells were specific for p53
, p53
, or p53
neoantigens, including a 78% reactive T-cell culture against p53
and HLA-A*02:01. Tracking
clonotypes (clonality, top ranked, and
mutation-specific) supported the enrichment of p53 neoantigen-reactive T cells from PBLs. The same T-cell receptor (TCR) from the TIL was found in the IVS cultures in three cases and multiple unique TCRs were found in another patient.
mutation-specific T cells also recognized tumor cell lines bearing the appropriate human leukocyte antigen restriction element and
mutation, indicating these T cells could recognize processed and presented p53 neoantigens.
PBL was a noninvasive source of T cells targeting
mutations for cell therapy and can provide a window into intratumoral p53 neoantigen immune responses.
. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-19-1874 |